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effect on T-cell subsets.Table 1
Risk Factor and IDO Activity Correlations for GVHD
Clinical Characteristics and GVHD
Risk Factors
GVHD
(n¼ 13)
No GVHD
(n ¼7)
P value
Age at HSCT, median (range) years 20 (2-69) 31 (1-49) 1.000*
Malignant disease, n (%) 10 (76.9) 7 (100.0) 0.521#
Non-malignant disease, n (%) 3 (23.1) 0
Malignant Disease Status at HSCT
CR1 3 (23.1) 3 (42.9) 0.415#
CR2 4 (30.8) 1 (14.3)
Active/Refractory 3 (23.1) 3 (42.9)
Conditioning Regimen
Myeloablative 7 (53.8) 5 (71.4) 0.484#
Reduced-intensity 6 (46.2) 2 (28.6)
HSCT Product
Bone marrow 6 (46.2) 1 (14.3) 0.199#
Peripheral Blood 5 (38.5) 3 (42.9)
Umbilical cord blood 2 (15.3) 3 (42.9)
HLA-Mismatch
0 9 (69.2) 4 (57.1) 0.207#
1 4 (30.8) 1 (14.3)
2 0 2 (28.6)
Unrelated Donor 9 (69.2) 5 (71.4) 1.000#
CD34+ cells/kg dose 3.63 x 106 3.19 x 106 0.757*
TNC cells/kg dose 4.81 x 108 4.18 x 108 0.699*
Post-HSCT Disease Relapse, n (%) 6 (46.2) 2 (28.6) 0.642#
Kyn/Trp (IDO) Ratio, median
(range)
1.55
(0.41-
15.15)
0.69
(0.16-2.06)
0.027*
AUC (Kyn/Trp IDO Ratio), median
(range)
43.20
(6.10-
666.80)
11.76
(8.03-35.49)
0.007*458
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Background: Grip strength and 2 minute walk test have
been suggested as elements of chronic graft-vs-host disease
(GVHD) assessment in clinical trials.
Methods: Using all available data (n¼584, 1,689 follow-up
visits, total of 2,273 visits) from a prospective observational
cohort study, we explored the relationship between grip
strength and 2 minute walk test and patient-reported
outcomes (Lee symptomscale, SF-36 and FACT-BMTquality of
life instruments, andHuman Activity Proﬁle, or HAP), chronic
GVHD severity (NIH global 0-3 score, clinician global 0-3
score, and patient-reported global 0-3 score) and mortality
(overall survival (OS) and non-relapse mortality (NRM)) in
multivariate analyses adjusted for signiﬁcant covariates.
Results: In multivariate analysis, 2 minute walk test was
signiﬁcantly ( P < .001) associated with intuitive domains of
the Lee Symptom Scale (overall, skin, lung, energy), while
grip strength was not. Excepting MCS (mental component
score), 2 minute walk test had signiﬁcant associationwith all
studied SF-36 domain and summary scores ( P < .001) and
FACT summary and domain scores ( P < .001). Both grip
strength and 2 minute walk test had signiﬁcant association
with FACT summary scores and HAP (maximum activity
score (MAS), and adjusted activity score (AAS)). In univariate
analysis using all visit data, 2minutewalk test had signiﬁcant
association with global chronic GVHD severity, as calculated
from organ scores, reported by clinicians, and reported by
patients ( P < .01). Patients with NIH global score of mild or
less and moderate achieved on average 20.7 and 15.3 feet,
respectively, greater distance covered compared to those
with NIH severe chronic GVHD. Conversely, grip strength had
no signiﬁcant association with any of these measures of
chronic GVHD. In time-varying multivariate models exam-
ining all data and adjusting for signiﬁcant covariates, 2
minute walk test was signiﬁcantly associated with both OS
and NRM (both P < .001), while no association was found for
grip strength.
Conclusions: Based on its consistent association with
symptom burden, QOL, chronic GVHD severity andmortality,
these data support the 2 minute walk test as a useful
measure in chronic GVHD assessment.459
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Background: Indoleamine 2,3-dioxygenase (IDO), the rate
limiting enzyme of tryptophan metabolism, in part mediates
allogeneic tolerance and may be important in allogeneic
HSCTand GVHD.
Objective: To prospectively evaluate in vivo IDO activity in
allogeneic HSCT recipients and test our hypothesis that IDO
activity is associated with acute GVHD.
Methods: Patients (>1 year-old) receiving allogeneic HSCT
were eligible. Plasma samples were collected at baseline and
days -3, 0, +7, 14, 21, 30, 45, 60, 100, 180, and 365 relative to
HSCT for tryptophan (Trp) and kynurenine (Kyn) quantiﬁca-
tion (mM) by high performance liquid chromatography.
Mann-Whitney rank tests were used to test associations
betweenKyn/Trp ratio (IDO activity) and area under the curve
(AUC) Kyn/Trp ratio and GVHD. Potential confounders were
tested for associationwith GVHDusing Fisher's exact tests (#)
or Mann-Whitney rank tests (*). Analyses were performed
using R (ver 2.12.1) and GraphPad Prism (ver 5.04).
Results: Twenty patients were evaluable for IDO activity and
GVHD. AMLwas themost common diagnosis (n¼ 9, 45%). All
patients engrafted atmean (SD) 17.2 (+/- 5) days. Acute GVHD
occurred in 13 (59.1%) patients: 10 were Grade I-II and 3were
Grade III.Median time toGVHDdiagnosiswas 46 days. Table 1
Table 1
Characteristics N¼20
Median age; years (range) 59 (26-72)
Male (%) 13 (65%)
Diagnosis, no. (%)
Acute Myeloid Leukemia 4 (20%)
Non-Hodgkin Lymphoma 11 (55%)
Chronic Leukemia (CLL or CML) 4 (20%)
Hemophagocytic syndrome 1 (5%)
Disease risk, no. (%)
High risk 5
Intermediate risk 10
Low risk 4
Prior autografting, no. (%)
Yes 1 (5%)
No 19 (95%)
Donors, no. (%)
Related 5 (25%)
Unrelated 15 (75%)
Sex mismatch, no (%)
M to M 9 (45%)
M to F 3 (15%)
F to M 4 (20%)
F to F 4 (20%)
Degree of HLA match, no. (%)
10/10 19 (95%)
9/10 1 (5%)
Median KPS; (range) 80 (70-100)
Median HCT-CI; (range) 1 (0-5)
Median CD34 cell dosey (106 cells/kg recipient body weight),
(range)
5.7 (1.5-11.3)
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with GVHD compared to non-GVHD cohort (p ¼ 0.027).
LikewiseAUCKyn/Trp ratio correlatedwithGVHD (p¼0.007).
Mortality rate was 50% at a median of 98 days post-HSCT.
Conclusions: IDO activity is associated with acute GVHD and
may be a useful biomarker to assist with GVHD diagnosis.
Future validation studies are needed to conﬁrm these ﬁnd-
ings, which should be considered in clinical trials that target
IDO induction for prevention or treatment of GVHD
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We have used home care as an option to hospital-care during
the pancytopenic phase after hematopoietic allogeneic stem
cell transplantation (HSCT) for 15 years at Karolinska
University Hospital . This is now an opportunity for children
as well as for adults. A nurse from the unit visited and
checked the patient regularly.
After treating 146 patients at home we compared them to
hospital controls matched for sex, age, diagnosis, stage of
disease, type of donor, source of stem cells and conditioning.
Oral intake was intensiﬁed from September 2006 and
improved (P ¼ .002). More calories per day was associated
with less GVHD in an univariate analysis (P ¼ .02). In multi-
variate analysis grades 0eI GVHD was associated with home
care (HR¼2.46, P ¼ .02) and with days spent at home
(HR¼0.92, P¼ .005), but notwith oral nutrition (HR¼0.98, P¼
.13). Transplant-related mortality, chronic GVHD and relapse
were similar in the groups. Five-year survival was 61% in the
home care group as compared to 49% in the controls (P¼ .07).
When we analyzed outcome of HSCT for the past two
decades, we found that low transplant-related mortality
(TRM) was associated with age (P < .001), acute leukemia (P
¼ .002), HLA-identical related donor (P < .001), reduced
intensity conditioning (P ¼ .007) and home care (P ¼ .02).
Wecollectedall in-andoutpatient costsduring twoyearsatour
unit. Costsduring the initial transplantperioduntil day76were
signiﬁcantly lowerwith home care inmultivariate analysis (RH
0.8,P ¼ .035). Increased costs were associated with a second
transplant, T-cell depletion, adults, G-CSF and complications.
To show Quality of life we used The Sympathy- Acceptance-
Understanding-Competence-questionnaire (SAUC) instrument
developed from the SAUC-model. This study aim to describe
patients’ experiences of care and support from healthcare staff
while treated in hospital or at home during the early post
transplantationphase afterHSCT. The studyshowedhomecare
to beas satisfactoryashospital-care. Also24 relatives staying at
home together with the patients gave their opinion regarding
quality of life. Eleven questions were asked in a survey with
a scale from 1-5 where 1 was very satisfactory and 5 was the
opposite. 21 rated 1-2 very satisfactory and three rated 2-3.
Conclusion: Home care is safe and cheaper than hospital
care. Home care and many days spent at home were corre-
lated with a low risk of acute GVHD. Home care was also
associated with a lower TRM and a trend for better survival.461
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Non-myeloablative (NMA) conditioning with total lymphoid
irradiation and antithymocyte globulin (TLI/ATG) has been
shown to protect against acute graft-versus-host disease
(GVHD), while preserving graft-versus-malignancy effects.
Reported here is our institutional experience with allogeneic
hematopoietic cell transplantation (allo-HCT) following TLI/
ATG conditioning. Criteria used to select TLI/ATG condi-
tioning included; age 65 and/or HCT-CI of >3. Patients
received ATG (1.5 mg/kg/day) from day -11 through -7 and
a total dose of 8Gy of TLI administered from day -11 through
-1 followed by cell infusion of day 0. GVHD prophylaxis
consisted of combination of either cyclosporine/mycophe-
nolate mofetil (MMF) or tacrolimus/MMF in those under-
going a matched sibling or unrelated donor allo-HCT,
respectively. Table 1 summarizes the baseline patient char-
acteristics (n¼20). The median follow up for surviving
patients is 723 days (range 180-1364 days). All patients
engrafted, except onewho experienced primary engraftment
failure. The median time to neutrophil engraftment was 16
days (range 9-23 days) and platelet engraftment was 10 days
(range 6-24 days). Median donor chimerism on days +30,
+100 and +365 was 93% (range 60-100%), 95% (range 54-
